Remove 2025 Remove Competition Remove Patients
article thumbnail

Top Challenges for Pharma Marketing in 2025

Pharma Marketing Network

The world of pharma marketing is changing rapidly, and 2025 will be no exception. From digital transformation and personalized marketing to compliance and competition, the upcoming years will demand flexibility and innovative thinking. So, what will be the top challenges in 2025, and how can pharma marketers tackle them?

article thumbnail

What Matters Most: The Three Trends That Will Change Pharma Marketing in 2025

Eversana Intouch

2: the direct-to-patient model ) in a paradigm that’s interconnected (No. In this report, 15 of our experts examine the current impact of each of these three forces, predict how you’ll see their effects in 2025 and give recommendations for how to make these market forces work for you. Technology (No.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Power of Healthcare Branding: Strategies for Pharma Marketing Success in 2025

Pharma Marketing Network

In an increasingly competitive pharmaceutical landscape, the significance of healthcare branding has never been more pronounced. As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success.

article thumbnail

op Pharma Marketing Trends Shaping the Future of Healthcare in 2025

Pharma Marketing Network

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As patients become more digitally savvy, pharma companies are investing in creating seamless digital experiences that cater to their needs and preferences.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

When patients experience intense emotion, either positive or negative, they are rendered unconscious. But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up.

article thumbnail

Life sciences response to 2024 Autumn Budget

European Pharmaceutical Review

Commitment to manufacturing the £520 million life sciences innovative manufacturing fund is very welcome, and will be crucial in helping to capture high-productivity investment” The Association of the British Pharmaceutical Industry (ABPI) backed the proposed measures to enhance life sciences competitiveness in the UK.

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

Sustainable biosimilar competition in Europe: can it be achieved? He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.” Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We